公开(公告)号：US20130165343A1

公开(公告)日：2013-06-27

申请号：US13775928

申请日：2013-02-25

申请人： AVEO Pharmaceuticals, Inc.

发明人： Murray Robinson ,  Bin Feng ,  Richard Nicoletti ,  Joshua P. Frederick ,  Lejla Pilipovic

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

摘要： Methods for identifying multigene biomarkers for predicting sensitivity or resistance to an anti-cancer drug of interest, or multigene cancer prognostic biomarkers are disclosed. The disclosed methods are based on the classification of the mammalian genome into 51 transcription clusters, i.e., non-overlapping, functionally relevant groups of genes whose intra-group transcript levels are highly correlated. Also disclosed are specific multigene biomarkers for predicting sensitivity or resistance to tivozanib, or rapamycin, and a specific multigene biomarker for determining breast cancer prognosis, all of which were identified using the methods disclosed herein.

公开(公告)号：US20180195120A1

公开(公告)日：2018-07-12

申请号：US15823227

申请日：2017-11-27

申请人： AVEO Pharmaceuticals, Inc.

发明人： Sylvie Vincent ,  Kristan Meetze ,  Bin Feng ,  Steven Tyler ,  Steve Bottega ,  Richard Nicoletti ,  Donna McIntosh ,  Jeno Gyuris

IPC分类号： C12Q1/6881 ,  G01N33/574 ,  A61K39/395

CPC分类号： C12Q1/6881 ,  A61K39/39558 ,  G01N33/574

摘要： A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.

公开(公告)号：US09828635B2

公开(公告)日：2017-11-28

申请号：US14349916

申请日：2012-10-05

申请人： AVEO Pharmaceuticals, Inc.

发明人： Sylvie Vincent ,  Kristan Meetze ,  Bin Feng ,  Steven Tyler ,  Steve Bottega ,  Richard Nicoletti ,  Donna McIntosh ,  Jeno Gyuris

IPC分类号： A61K39/395 ,  C12Q1/68 ,  G01N33/574

CPC分类号： C12Q1/6881 ,  A61K39/39558 ,  G01N33/574

摘要： A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.

公开(公告)号：US20140242597A1

公开(公告)日：2014-08-28

申请号：US14349916

申请日：2012-10-05

申请人： AVEO PHARMACEUTICALS, INC.

发明人： Sylvie Vincent ,  Kristan Meetze ,  Bin Feng ,  Steven Tyler ,  Steve Bottega ,  Richard Nicoletti ,  Donna McIntosh ,  Jeno Gyuris

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6881 ,  A61K39/39558 ,  G01N33/574

摘要： A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.

摘要翻译： 公开了一种诊断方法，用于定量地预测人肿瘤是否对ERBB3抑制剂例如抗ERBB3抗体的治疗敏感或抗性。 该方法基于来自肿瘤的组织样品中RNA水平或蛋白质水平的NRG1表达的测量。

公开(公告)号：US20140045715A1

公开(公告)日：2014-02-13

申请号：US13958836

申请日：2013-08-05

申请人： AVEO Pharmaceuticals, Inc.

发明人： Jie Lin ,  Bin Feng ,  Murray Robinson ,  Feng Jiang ,  Xiaojian Sun

IPC分类号： G01N33/574 ,  C12Q1/68

CPC分类号： G01N33/57492 ,  C12Q1/6886 ,  G01N33/57407 ,  G01N2333/70596 ,  G01N2800/52

摘要： A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry.

摘要翻译： 公开了一种诊断方法，用于预测人肿瘤是否敏感或对利托那尼治疗有抗药性（AV-951）。 该方法基于来自肿瘤的组织样品中巨噬细胞含量的测量。 巨噬细胞含量的测定可以基于巨噬细胞标记基因表达的分析，例如通过RNA分析或免疫组织化学。

公开(公告)号：US20130165337A1

公开(公告)日：2013-06-27

申请号：US13669275

申请日：2012-11-05

申请人： AVEO PHARMACEUTICALS, INC.

发明人： Murray Robinson ,  Bin Feng ,  Richard Nicoletti ,  Joshua P. Frederick ,  Lejla Pilipovic

IPC分类号： C40B30/04 ,  C40B40/06

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

摘要： Methods for identifying multigene biomarkers for predicting sensitivity or resistance to an anti-cancer drug of interest, or multigene cancer prognostic biomarkers are disclosed. The disclosed methods are based on the classification of the mammalian genome into 51 transcription clusters, i.e., non-overlapping, functionally relevant groups of genes whose intra-group transcript levels are highly correlated. Also disclosed are specific multigene biomarkers for predicting sensitivity or resistance to tivozanib, or rapamycin, and a specific multigene biomarker for determining breast cancer prognosis, all of which were identified using the methods disclosed herein.

摘要翻译： 公开了用于鉴定用于预测感兴趣的抗癌药物或多基因癌症预后生物标志物的敏感性或抗性的多基因生物标志物的方法。 所公开的方法基于将哺乳动物基因组分类为51个转录簇，即组内转录水平高度相关的非重叠功能相关基因组。 还公开了用于预测对利托那尼或雷帕霉素的敏感性或抗性的特异性多基因生物标志物，以及用于确定乳腺癌预后的特异性多基因生物标志物，所有这些标记均使用本文公开的方法鉴定。